Lakewood-Amedex Biotherapeutics Inc. – What You Need to Know

Thinking about investing in Lakewood-Amedex? Before you put your hard-earned money on the line, let’s break down what this company is actually doing in plain English.

1. What does this company actually do?

Think of Lakewood-Amedex as a drug discovery lab. They are tackling a major global health crisis: antibiotic-resistant bacteria, or "superbugs" that current medicine cannot kill.

Their "secret sauce" is a class of drugs called Bisphosphocins®. Traditional antibiotics target specific parts of bacteria that can mutate to resist treatment. Bisphosphocins® work differently; they kill bacteria rapidly by destroying their cell membranes. This design aims to stop resistance from developing.

Their lead project, Nu-3, is a topical gel for infected diabetic foot ulcers. They are also using this technology to research treatments for urinary tract and lung infections, though these projects are still in the early stages.

2. How do they make money?

Right now, they don't. They are in the research phase, meaning they spend money to prove their science works rather than selling products. As of December 31, 2025, they had only about $236,400 in cash. Because they spend millions annually on research and operations, they have more debt than assets. The company has stated there is significant doubt about their ability to stay in business without raising more money.

3. What’s the deal with their recent financing?

In April 2026, the company raised $7.5 million by selling "Series C Preferred Stock." These shares have a "variable conversion price." If the company’s stock price falls, the conversion price drops, allowing these investors to get more common shares. For you, this creates a high risk of dilution—meaning the company issues more shares, which reduces your ownership percentage and the value of your stake.

4. What are the main risks?

• The "Clinical Trial" Gauntlet: Biotech is a long, expensive, and risky road. The company must navigate complex FDA rules, recruit enough patients, and figure out how to manufacture drugs at scale. Many drug candidates fail in large-scale trials, even if early results look good.
• The "Bias" Trap: Some of their data comes from "open-label" studies, where patients and doctors know who is receiving the treatment. This can introduce bias, making the results less reliable than the "double-blind" studies that regulators prefer.
• The "Cash Crunch": The company burns through cash faster than it earns it. They rely entirely on raising more money through debt or selling shares. Any future fundraising will likely dilute your shares further, and there is no guarantee they can find the money they need.
• The "Small Company" Exemptions: As an "emerging growth company," Lakewood-Amedex follows reduced reporting rules. You get less historical data and fewer internal financial disclosures than you would with a mature company.

5. Where does it trade?

The company trades on the Nasdaq Capital Market under the ticker "LABT." As of May 13, 2026, the stock traded at $2.95 per share.

Final Thoughts for Investors

If you are considering an investment here, ask yourself if you are comfortable with the "binary" nature of biotech: the company will either succeed in bringing a breakthrough drug to market, or it may run out of cash trying.

A Friendly Reminder: Investing in biotech is like betting on a race where the finish line is years away. The stock price can be a roller coaster. Only invest money you are comfortable losing.

Disclaimer: I am an AI, not a financial advisor. This guide is for informational purposes only and does not constitute financial advice.